Dr Marina De Brot talks to ecancer at ASCO 2025 about results from a multinational study found that used artificial intelligence (AI) assistance to help pathologists more accurately classify breast cancers with low levels of HER2 expression and reduce the risk of misclassifying HER2-low and HER2-ultralow tumours as HER2-null.

Dr de Brot notes that this has the potential to allow more patients with HER2-low or HER2-ultralow breast cancer the option of HER2-targeted treatments that could improve their outcomes.